Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7743516 | 1.00 | KDM4E (0.57) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| SCHEMBL3319088 | 1.00 | KDM4E (0.57) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| SCHEMBL31669038 | 1.00 | KDM4E (0.57) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| Hydrochloric Acid SCHEMBL30377815 | 0.98 | KDM4E (0.60) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| Hydrochloric Acid SCHEMBL8702078 | 0.98 | KDM4E (0.60) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| Hydrochloric Acid SCHEMBL8121954 | 0.98 | KDM4E (0.60) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| SCHEMBL27957676 | 0.90 | KDM4E (0.49) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| SCHEMBL17918582 | 0.86 | KMT2A (0.45) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| SCHEMBL7435456 | 0.85 | KDM4E (0.49) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 | |
| Hydrochloric Acid SCHEMBL7745991 | 0.83 | KDM4E (0.51) | KDM4ECYP1A2CYP2D6CYP2C9MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC | 2019-11-14 | — | — | US | disclosed |
| WO-2018045246-A1 | CXCR3 RECEPTOR AGONISTS | CELGENE INTERNATIONAL II SARL (CH) | 2018-03-08 | — | — | WO | disclosed |
| US-9783573-B2 | IAP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783573-B2 | IAP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-10 | — | — | US | disclosed |
| US-20150322111-A1 | IAP ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2015-11-12 | — | — | US | disclosed |
| US-20150322111-A1 | IAP ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2015-11-12 | — | — | US | disclosed |
| WO-2014047024-A1 | IAP ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-27 | — | — | WO | disclosed |
| EP-1045843-A4 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2001-10-24 | — | — | EP | disclosed |
| EP-1045843-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2000-10-25 | — | — | EP | disclosed |
| US-5977134-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-11-02 | — | — | US | disclosed |
| WO-1999028313-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1999-06-10 | — | — | WO | disclosed |
| EP-0061186-B1 | DIPEPTIDES CONTAINING THIALYSINE AND HOMOLOGS AS ANTIHYPERTENSIVES | MERCK & CO. INC. (US) | 1986-05-21 | — | — | EP | disclosed |
| US-4512979-A | Dipeptides containing thialysine and related amino acids as antihypertensives | MERCK & CO., INC. (US) | 1985-04-23 | — | — | US | disclosed |
| EP-0065301-A1 | Isoquinoline carboxylic acid derivates, process for preparing and pharmaceutical composition containing the same | MERCK & CO. INC. (US) | 1982-11-24 | — | — | EP | disclosed |
| EP-0061186-A1 | Dipeptides containing thialysine and homologs as antihypertensives | MERCK & CO. INC. (US) | 1982-09-29 | — | — | EP | disclosed |
| EP-0018549-B1 | TETRAHYDROISOQUINOLINE COMPOUNDS, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Tanabe Seiyaku Co., Ltd. (JP) | 1981-12-30 | — | — | EP | disclosed |
| US-4294832-A | HYPOTENSIVE AGENTS, ANGIOTENSIN INHIBITORS | TANABE SEIYAKU CO., LTD. (JP) | 1981-10-13 | — | — | US | disclosed |
| EP-0018549-A2 | Tetrahydroisoquinoline compounds, process for preparing them and pharmaceutical compositions containing them | Tanabe Seiyaku Co., Ltd. (JP) | 1980-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322111-A1 | IAP ANTAGONISTS | XIAP, BIRC5, API5 | KDM4E 3652/4885CYP1A2 4826/4885CYP2D6 4842/4885 |
| US-11040954-B1 | CXCR3 receptor agonists | CXCR3, CXCR1, CCR7 | KDM4E 4161/4885CYP1A2 1702/4885CYP2D6 2230/4885 |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | CXCR3, CXCR1, CCR7 | KDM4E 4161/4885CYP1A2 1702/4885CYP2D6 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.